Efficacy of Aspirin in Preventing Venous Thromboembolism

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado60 enrolled

Overview

Efficacy of aspirin and enoxaparin in preventing venous tromboembolism was compared after total knee or hip arthroplasty.

Background: Venous thromboembolism (VTE) remains a significant risk following joint replacements, despite advancements in prevention strategies. Aspirin-based therapies have gained popularity due to their perceived safety, ease of administration, and supportive evidence.This study aimed to compare the efficacy of aspirin and enoxaparin in preventing VTE after total knee or hip arthroplasty. Methods: Sixty patients undergoing primary total knee or hip arthroplasty were randomized to receive either aspirin or enoxaparin. The primary outcome was symptomatic VTE within 90 days. Patients were followed up for Doppler ultrasound evaluations.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Venous Thromboembolism (VTE)Total Joint Arthroplasty Total Hip Arthroplasty (THA)

Interventions

AspirinDRUG

100 mg/day orally for 25 days

enoxaparinDRUG

40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * All patients provided written informed consent. * All patients who underwent primary total hip or total knee arthroplasty for osteoarthritis Exclusion Criteria: * preoperative anticoagulation (direct oral anticoagulant, warfarin, IMPROVE Bleeding Score more or equal to 7, dual antiplatelet therapy) * medical contraindications (allergy, cancer, cardiac disease, kidney disease, or bleeding disorder precluding anticoagulation).

Locations (1)

ISSSTEP

Puebla City, Mexico

Outcomes

Primary Outcomes

Symptomatic VTE

Time frame: 90 days

Secondary Outcomes

Wound bleeding

Time frame: 90 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.